Welcome to LookChem.com Sign In|Join Free

CAS

  • or

200002-41-1

Post Buying Request

200002-41-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 2-Azabicyclo[2.2.1]hept-5-ene-2-carboxylic acid, 3-oxo-,1,1-dimethylethyl ester, (1S,4R)-

    Cas No: 200002-41-1

  • No Data

  • No Data

  • No Data

  • shyrchem
  • Contact Supplier

200002-41-1 Usage

Property

Tert-butyl ester of a bicyclic beta-lactam compound

Check Digit Verification of cas no

The CAS Registry Mumber 200002-41-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,0,0 and 2 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 200002-41:
(8*2)+(7*0)+(6*0)+(5*0)+(4*0)+(3*2)+(2*4)+(1*1)=31
31 % 10 = 1
So 200002-41-1 is a valid CAS Registry Number.

200002-41-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name (-)-[(1R,4S)-tert-butyl 3-oxo-2-azabicyclo(2.2.1)hept-5-ene-2-carboxylate]

1.2 Other means of identification

Product number -
Other names (1S,4R)-(+)-2-N-boc-azabicyclo[2.2.1]hept-5-ene-3-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:200002-41-1 SDS

200002-41-1Relevant articles and documents

Regio- and Stereoselective Ring-Opening Metathesis Polymerization of Enantiomerically Pure Vince Lactam

Benedikter, Mathis J.,Frater, Georg,Buchmeiser, Michael R.

, p. 2276 - 2282 (2018)

The ring-opening metathesis polymerization (ROMP) of (+)-Vince lactam [(S)-azabicyclo[2.2.1]hept-5-en-3-one] (1) and its N-benzyl, N-trimethylsilyl (TMS), and N-tert-butoxycarbonyl (Boc) derivatives (2a-c) is reported. Highly cis-syndiotactic (st) poly(Vince lactam) was readily accessible by using the cyclometalated ruthenium complex Ru[CH(2-OiPr-Ph)](Piv)(1-mesityl-3-C4H8-imidazol-2-ylidene) (Piv =2,2-dimethylpropanoate) (4); however, small amounts of trans double bonds (ca. 5%) formed. Highly cis-st (>98%) polymers were accessible by the action of the monoaryloxide pyrrolide (MAP) type complexes W(N-2,6-iPr2C6H3)(CHCMe2Ph)(Pyr)(HMTO) (Pyr = pyrrolide, HMTO = 2,6-(2,4,6-Me3C6H2)2C6H3O) (7) and W(O)(CHCMe2Ph)(PMe2Ph)(Me2Pyr)(TPPO) (TPPO = 2,3,5,6-tetraphenylphenolate) (8). Complementary, cis-isotactic (>98% cis-it) polymers were prepared by the action of Mo(N-2,6-Me2C6H3)(CHCMe2Ph)(OBiphen) (OBiphen = 3,3′-di-tert-butyl-5,5′,6,6′-tetramethyl-1,1′-biphenyl-2,2′-diolate) (5) and its tungsten analogue W(N-2,6-Me2C6H3)(CHCMe2Ph)(OBiphen) (6). Notably, none of these Mo- and W-based initiators polymerize unprotected Vince lactam. Deprotection of poly(N-TMS Vince lactam) and poly(N-Boc Vince lactam) with neat trifluoroacetic acid allowed for the isolation of all-cis highly tactic poly(Vince lactam).

3-CARBON SUBSTITUTED 4-AMINOCYCLOPENT-1-ENE-1-CARBOXYLIC ACID COMPOUNDS AS INHIBITORS OF GAMMA-AMINOBUTYRIC ACID (GABA) AMINOTRANSFERASE

-

Paragraph 0102; 0106, (2019/10/29)

Disclosed are cyclopentene compounds for use as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase (AT) and/or ornithine aminotransferase (OAT). The disclosed cyclopentene compounds include 3-carbon substituted 4-aminocyclopent-1-ene-carboxylic acid compounds which may be formulated in pharmaceutical composition for treating diseases and disorders associated with GABA-AT and/or OAT activity, including epilepsy, addiction, and hepatocellular carcinoma (HCC).

SPIRO [2.4]HEPTANES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS

-

, (2013/08/28)

Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 200002-41-1